Dr. Hans van Eenennaam is founder and CEO of IMMIOS, CSO at Sairopa and independent BOD member at ISD Immunotec AsP, Catalym GmBH and Lygature. Previously he served as CSO of AIMM Therapeutics, Executive Vice President of Antibody Research and Site Head for Aduro Biotech Europe. In 2015, Aduro Inc. acquired BioNovion, a company that van Eenennaam co-founded in 2011. Earlier in his career, he held positions of increasing responsibility at Organon, Schering-Plough and  MSD/Merck. He was involved in the discovery and development of pembrolizumab (Keytruda®), MK-5890 (CD27), BION-1301 (APRIL), ADU-1604 (CTLA-4) and ADU-1805 (SIRP).  In 2016, he was awarded the Inventor of the Year Award. Dr. van Eenennaam is a chemist by training and received his doctorate (cum laude) in autoimmune biochemistry from Radboud University in Nijmegen.